{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:39:10Z","timestamp":1790851150469,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council of Singapore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Singapore Ministry of Education","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011105","name":"Yong Loo Lin Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011105","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NUHS Basic Seed Fund"},{"name":"Ministry of Education Tier 1"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ctrv.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T05:19:08Z","timestamp":1510291148000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"special_numbering":"C","title":["Triple negative breast cancer in Asia: An insider\u2019s view"],"prefix":"10.1016","volume":"62","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianning","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanpei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Arfuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Lobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina H.K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.10.014_b0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.canep.2014.08.004","article-title":"Breast cancer in South Asia: a Bangladeshi perspective","volume":"38","author":"Hossain","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0010","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","article-title":"Is breast cancer the same disease in Asian and Western countries?","volume":"34","author":"Leong","year":"2010","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2017.10.014_b0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.10.014_b0020","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0025","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr1636","article-title":"Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival","volume":"9","author":"Fulford","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0030","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0035","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0002-9440(10)64476-8","article-title":"Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome","volume":"161","author":"van de Rijn","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0040","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2017.10.014_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.10.014_b0050","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/548.6505","article-title":"Triple-negative breast cancer: current state of the art","volume":"96","author":"Rastelli","year":"2010","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2017.10.014_b0060","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2017.10.014_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/modpathol.2009.145","article-title":"Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer","volume":"23","author":"Thike","year":"2010","journal-title":"Modern Pathol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2780","article-title":"Lifetime risks of specific breast cancer subtypes among women in four racial\/ethnic groups","volume":"12","author":"Kurian","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0080","unstructured":"Sajid MT, Ahmed M, Azhar M, Mustafa QU, Shukr I, Ahmed M, et al. Age-related frequency of triple negative breast cancer in women. J College Phys Surg \u2013 Pakistan: JCPSP 2014;24:400\u20133."},{"key":"10.1016\/j.ctrv.2017.10.014_b0085","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.7314\/APJCP.2014.15.11.4507","article-title":"Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre","volume":"15","author":"Sharma","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ctrv.2017.10.014_b0090","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.7314\/APJCP.2013.14.6.3779","article-title":"Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ctrv.2017.10.014_b0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4048\/jbc.2014.17.2.129","article-title":"Characteristics of BRCA1\/2 mutation-positive breast cancers in Korea: a comparison study based on multicenter data and the Korean breast cancer registry","volume":"17","author":"Yu","year":"2014","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2047-783X-19-35","article-title":"The prevalence of BRCA1\/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China","volume":"19","author":"Li","year":"2014","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0105","doi-asserted-by":"crossref","first-page":"e0134408","DOI":"10.1371\/journal.pone.0134408","article-title":"Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population","volume":"10","author":"Wong","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.10.014_b0110","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/bcr3347","article-title":"Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer","volume":"14","author":"Phuah","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2015.06.009","article-title":"Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer","author":"Yamashita","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clbc.2014.05.003","article-title":"Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea","volume":"14","author":"Lee","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0125","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","article-title":"Risk factors for triple-negative breast cancer in women under the age of 45 years","volume":"18","author":"Dolle","year":"2009","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ctrv.2017.10.014_b0130","unstructured":"United Nations E, Social Commission for A, the Pacific EPDF, Family Planning S. The use of contraception in the Asian and Pacific region. Popul Res Leads 1985:1\u201331."},{"key":"10.1016\/j.ctrv.2017.10.014_b0135","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/annonc\/mdv379","article-title":"Breastfeeding and breast cancer risk by receptor status \u2013 a systematic review and meta-analysis","volume":"26","author":"Islami","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0140","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s12032-009-9308-7","article-title":"A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China","volume":"27","author":"Xing","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0145","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1055-9965.EPI-08-0544","article-title":"Triple-negative breast cancer and obesity in a rural Appalachian population","volume":"17","author":"Vona-Davis","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ctrv.2017.10.014_b0150","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/bcr2261","article-title":"Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors","volume":"11","author":"Kwan","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3346\/jkms.2016.31.6.886","article-title":"Being overweight or obese increases the risk of progression in triple-negative breast cancer after surgical resection","volume":"31","author":"Choi","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ctrv.2017.10.014_b0160","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-08-0206","article-title":"Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women","volume":"17","author":"Phipps","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ctrv.2017.10.014_b0165","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/EDE.0000000000000373","article-title":"Modifiable lifestyle factors and triple-negative breast cancer survival: a population-based prospective study","volume":"26","author":"Bao","year":"2015","journal-title":"Epidemiology"},{"key":"10.1016\/j.ctrv.2017.10.014_b0170","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2017.10.014_b0175","doi-asserted-by":"crossref","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database","volume":"95","author":"Plasilova","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctrv.2017.10.014_b0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-014-3225-y","article-title":"Reduced risk of axillary lymphatic spread in triple-negative breast cancer","volume":"149","author":"Holm-Rasmussen","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.014_b0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-016-3757-4","article-title":"Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study","volume":"156","author":"van Roozendaal","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.014_b0190","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/ol.2014.2333","article-title":"Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer","volume":"8","author":"Sawaki","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2017.10.014_b0195","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3349\/ymj.2016.57.5.1192","article-title":"Comparisons of oncologic outcomes between Triple-Negative Breast Cancer (TNBC) and non-TNBC among patients treated with breast-conserving therapy","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ctrv.2017.10.014_b0200","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1245\/s10434-014-4090-y","article-title":"Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery","volume":"22","author":"Chung","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0205","doi-asserted-by":"crossref","first-page":"385978","DOI":"10.1155\/2012\/385978","article-title":"Triple-negative breast cancer: an update on neoadjuvant clinical trials","volume":"2012","author":"Amos","year":"2012","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0210","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0215","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0220","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0225","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0235","first-page":"770","article-title":"Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer","volume":"34","author":"Ma","year":"2012","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.ctrv.2017.10.014_b0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1513749","article-title":"Adaptive randomization of veliparib-carboplatin treatment in breast cancer","volume":"375","author":"Rugo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.10.014_b0245","first-page":"381","article-title":"Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients","volume":"33","author":"Zhang","year":"2011","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.ctrv.2017.10.014_b0250","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/ol.2012.1093","article-title":"Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis","volume":"5","author":"Liu","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2017.10.014_b0255","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ijc.24090","article-title":"Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy","volume":"124","author":"Uhm","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0260","first-page":"S3","article-title":"The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer (CRUK\/07\/012)","author":"Tutt","year":"2014","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.ctrv.2017.10.014_b0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/15384047.2014.986973","article-title":"A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2017.10.014_b0270","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.28966","article-title":"Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer","volume":"136","author":"Zhang","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0275","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0280","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/annonc\/mds603","article-title":"Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer","volume":"24","author":"Fan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0285","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0290","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1158\/0008-5472.CAN-09-4521","article-title":"Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin","volume":"70","author":"Hastak","year":"2010","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0295","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.10.014_b0300","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.10.014_b0305","article-title":"A randomized Phase II study of veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in BRCA1\/2 metastatic breast cancer: design and rationale","author":"Isakoff","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2017.35.15_suppl.1007","article-title":"Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1\/2 mutations (ABRAZO)","volume":"35","author":"Turner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0315","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0320","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","article-title":"TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer","volume":"30","author":"Carey","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0325","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/annonc\/mds067","article-title":"Targeting triple-negative breast cancer: optimising therapeutic outcomes","volume":"23","author":"Gelmon","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0330","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OTT.S67673","article-title":"Triple-negative breast cancer: new perspectives for targeted therapies","volume":"8","author":"Tomao","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2017.10.014_b0335","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0340","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.10.014_b0345","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0350","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0355","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","article-title":"Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial","volume":"133","author":"Brufsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.014_b0360","first-page":"4773","article-title":"Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product","volume":"52","author":"Ottenhoff-Kalff","year":"1992","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0365","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","article-title":"Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study","volume":"17","author":"Finn","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0370","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2013.06.041","article-title":"Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells","volume":"185","author":"Kim","year":"2013","journal-title":"J Surg Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0375","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.18632\/oncotarget.6304","article-title":"Simvastatin-induced breast cancer cell death and deactivation of PI3K\/Akt and MAPK\/ERK signalling are reversed by metabolic products of the mevalonate pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.10.014_b0380","doi-asserted-by":"crossref","first-page":"T161","DOI":"10.1530\/ERC-14-0243","article-title":"Complexities of androgen receptor signalling in breast cancer","volume":"21","author":"McNamara","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0385","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsbmb.2012.08.007","article-title":"Androgen receptor in triple negative breast cancer","volume":"133","author":"McNamara","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0390","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.humpath.2007.07.007","article-title":"Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast","volume":"39","author":"Hanley","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0395","doi-asserted-by":"crossref","first-page":"e0128368","DOI":"10.1371\/journal.pone.0128368","article-title":"Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients","volume":"10","author":"Ricciardi","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.10.014_b0400","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1074\/mcp.M113.037176","article-title":"Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response","volume":"13","author":"Liu","year":"2014","journal-title":"Mol Cell Proteom: MCP"},{"key":"10.1016\/j.ctrv.2017.10.014_b0405","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0415","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-017-0011-0","article-title":"Dramatic response of metaplastic breast cancer to chemo-immunotherapy","volume":"3","author":"Adams","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0420","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","article-title":"Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2","volume":"35","author":"Nanda","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0425","article-title":"Breast cancer immunotherapy: facts and hopes","author":"Emens","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.10.014_b0430","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27929","article-title":"MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer","author":"Guo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2017.10.014_b0435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5483\/BMBRep.2015.48.6.031","article-title":"Yoon, FZD6 expression is negatively regulated by miR-199a-5p in human colorectal cancer","volume":"48","author":"Kim","year":"2015","journal-title":"BMB Rep"},{"key":"10.1016\/j.ctrv.2017.10.014_b0440","doi-asserted-by":"crossref","first-page":"e0124340","DOI":"10.1371\/journal.pone.0124340","article-title":"Differentially expressed microRNAs in postpartum breast cancer in Hispanic women","volume":"10","author":"Munoz-Rodriguez","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.10.014_b0445","doi-asserted-by":"crossref","first-page":"16638","DOI":"10.18632\/oncotarget.3184","article-title":"Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer","volume":"6","author":"Rhodes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.10.014_b0450","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.febslet.2012.12.027","article-title":"Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells","volume":"587","author":"Yi","year":"2013","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2017.10.014_b0455","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/bjc.2015.143","article-title":"Circulating cell-free miRNAs as biomarker for triple-negative breast cancer","volume":"112","author":"Shin","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0460","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1172\/JCI64946","article-title":"TGF-beta upregulates miR-181a expression to promote breast cancer metastasis","volume":"123","author":"Taylor","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2017.10.014_b0465","doi-asserted-by":"crossref","first-page":"e96228","DOI":"10.1371\/journal.pone.0096228","article-title":"MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer","volume":"9","author":"Ouyang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.10.014_b0470","article-title":"Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer","author":"Niu","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2017.10.014_b0475","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/15476286.2015.1053687","article-title":"LncRNA BCAR4 wires up signaling transduction in breast cancer","volume":"12","author":"Xing","year":"2015","journal-title":"RNA Biol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0480","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.10.013","article-title":"LncRNA directs cooperative epigenetic regulation downstream of chemokine signals","volume":"159","author":"Xing","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2017.10.014_b0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-015-0318-0","article-title":"The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression","volume":"14","author":"Shi","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2017.10.014_b0490","doi-asserted-by":"crossref","unstructured":"Shen X, Xie B, Ma Z, Yu W, Wang W, Xu D, et al. Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget 2015.","DOI":"10.18632\/oncotarget.4419"},{"key":"10.1016\/j.ctrv.2017.10.014_b0495","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-010-0943-7","article-title":"DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer","volume":"127","author":"Germain","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.014_b0500","first-page":"756","article-title":"The DEAD box proteins DDX5 (p68) and DDX17 (p72): multi-tasking transcriptional regulators","volume":"2013","author":"Fuller-Pace","year":"1829","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/j.ctrv.2017.10.014_b0505","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/fon.11.1","article-title":"RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development","volume":"7","author":"Fuller-Pace","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2017.10.014_b0510","doi-asserted-by":"crossref","unstructured":"Wang D, Huang J, Hu Z. RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteom 2012;11:M111 011932.","DOI":"10.1074\/mcp.M111.011932"},{"key":"10.1016\/j.ctrv.2017.10.014_b0515","doi-asserted-by":"crossref","first-page":"e1002418","DOI":"10.1371\/journal.ppat.1002418","article-title":"Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis","volume":"7","author":"Cai","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ctrv.2017.10.014_b0520","doi-asserted-by":"crossref","first-page":"19136","DOI":"10.1074\/jbc.274.27.19136","article-title":"Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C","volume":"274","author":"Grundhoff","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2017.10.014_b0525","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI73451","article-title":"DEAD-box helicase DP103 defines metastatic potential of human breast cancers","volume":"124","author":"Shin","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2017.10.014_b0530","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00262-007-0331-2","article-title":"HAGE, a cancer\/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I\/II HAGE-derived immunogenic peptides","volume":"56","author":"Mathieu","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2017.10.014_b0535","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/bjc.2014.168","article-title":"HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer","volume":"110","author":"Abdel-Fatah","year":"2014","journal-title":"Br J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T04:49:28Z","timestamp":1656391768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217301846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":107,"alternative-id":["S0305737217301846"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.10.014","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple negative breast cancer in Asia: An insider\u2019s view","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}